Articles By Doug Roe

  1. Bioresorbable Polymers: The Next Generation In Stent Technology 5/20/2016

    Next-generation stent technology is and will be bio-absorbable or bioresorbable. To gain a richer understanding of the current trends, I sat down with Craig Thompson, MD, who is SVP/CMO of Boston Scientific’s Interventional Cardiology. Dr. Thompson also provided insight behind the SYNERGY Coronary Stent's development.

  2. 3 Vital Considerations For Medtechs Mulling A Hospital Partnership 5/5/2016

    Each medtech company must consider carefully how its products and services fit its customers’ needs. Some may pursue (or continue) a category-killer approach, and dominate a narrow channel. Others may choose to be market disrupters and produce game-changing technologies. Most of today’s medtech companies have taken a blended approach, but the opportunities to partner with providers in the new outcomes-based healthcare paradigm are enticing.

  3. Boston Scientific's Plan To Create Modular Pacing — A Chat With Dr. Ken Stein, SVP/CMO, Cardiac Rhythm Management 4/26/2016

    Med Device Online recently interviewed Dr. Ken Stein, SVP and chief medical officer at Boston Scientific CRM. Dr. Stein discussed his company’s yet-to-be-named, leadless micro pacer, where the device stands in development, and how Boston Scientific plans to combine its new pacing technology with its subcutaneous implantable defibrillator (S-ICD) to create a flexible modular system.

  4. Insiders' Guide To Winning In the Drug Delivery Device Market — Part 5: The Internet of Things 4/19/2016

    To learn more about how the IoT will impact medtech as a whole, and drug delivery in particular, I interviewed Stephen Wilcox, principal and founder of Design Science, Inc. We discussed his thoughts on trends in the drug delivery device market, how he sees the evolution of the IoT transforming healthcare technology, and what implications the technology holds for device developers.

  5. Will Funding Woes Doom The Next Generation Of Medtech Innovators? 4/8/2016

    With two full years of information now available since the Affordable Care Act’s passage, a disconcerting pattern has emerged affecting small companies and startups — the primary sources of new innovation, and the life blood of medtech. Will industry and market disruption created by the ACA lead to unintended, long-term restrictions for medtech innovation?

  6. Med Device Darwinism: Evolving Epinephrine Delivery 4/5/2016

    Last week, we spoke with Windgap Medical CEO Chris Stepanian about the challenges of entering the epinephrine delivery market, dominated by Mylan's EpiPen. This week, we go more in depth with the startup's CEO; he delves into Windgap Medical's device and development process in greater detail, and offers a peek behind the curtain at his company's down-the-road plans. 

  7. Keeping It Simple: One Startup's Plan To Upend The Epinephrine Delivery Market 3/29/2016

    What does it take to overcome the challenges in a market with a dominant, entrenched leader? Med Device Online recently had a chance to discuss the topic with Chris Stepanian, CEO of medtech startup Windgap Medical. Stepanian shared his views on those issues and detailed his company’s plan to evolve auto injector device technology.

  8. New AdvaMed CEO Scott Whitaker Discusses His Vision For Medtech 3/22/2016

    Part one of our interview with incoming AdvaMed CEO Scott Whitaker reviewed his start in advocacy and his career to this point. Part two of our conversation is a look forward to Whitaker’s plans — both for himself and for the organization — during his first year with the global medtech trade association, and beyond.

  9. From Biotech To Medtech: A Chat With New AdvaMed CEO Scott Whitaker 3/15/2016

    I recently interviewed new AdvaMed CEO Scott Whitaker. We discussed his early legislative background with the U.S. Department of Health and Human Services (HHS), as well as how he thinks his 11 years of experience at BIO will apply to his new position. 

  10. Insiders' Guide To Winning In The Drug Delivery Device Market — Part 4: Vertical Integration 2/23/2016

    The tenets of vertical integration can drive a complete combination product development strategy, as well as establish the internal core competencies needed to consistently execute that strategy. I recently sat down with Anand Subramony, VP of drug delivery and device development at Medimmune (the global biologics arm of AstraZeneca). We discussed his thoughts on trends in the drug delivery device market and how the business philosophies of vertical integration can play a role.